Trace Neuroscience launches with $101m funding

Trace Neuroscience launches with exclusive license from UCL and $101 million Series A funding to take forward potential new therapeutic for motor neurone disease.

Trace neuroscience team

Today sees the launch of Trace Neuroscience, Inc., a biopharmaceutical company whose co-founders include Professor Pietro Fratta (UCL) and Professor Aaron Gitler (Stanford).

Trace Neuroscience licensed intellectual property exclusively from UCL as part of the company formation.
Trace is developing antisense oligonucleotides to restore production of a key protein called UNC13A, which characterises almost all cases of ALS (motor neuron disease).

The $101m financing was led by Third Rock Ventures and included participation from Atlas Venture, GV and RA Capital Management.

UCL Ventures supported the academic team, working closely to protect the intellectual property and facilitating the collaboration.

Links:
- UCL Ventures story
- Trace Neuroscience website